医学
非诺贝特
危险系数
内科学
辛伐他汀
类降脂药
糖尿病
安慰剂
心肌梗塞
2型糖尿病
他汀类
2型糖尿病
置信区间
冲程（发动机）
内分泌学
机械工程
工程类
病理
替代医学
作者
Henry N. Ginsberg,Marshall B. Elam,Laura Lovato,John R. Crouse,Lawrence A. Leiter,Peter E. Linz,William T. Friedewald,John B. Buse,Hertzel C. Gerstein,Jeffrey L. Probstfield,Richard H. Grimm,Faramarz Ismail-Beigi,J. Thomas Bigger,David C. Goff,William C. Cushman,Denise G. Simons‐Morton,Robert P. Byington
标识
DOI：10.1056/nejmoa1001282
摘要
The combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with simvastatin alone. These results do not support the routine use of combination therapy with fenofibrate and simvastatin to reduce cardiovascular risk in the majority of high-risk patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00000620.)
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
cdercder
Kao
Nole
Copyright
Criminology34
学术文献互助
OK
斯文钢笔
伶俐妙海
yjh123
蓝天
Twonej
sagitar
初景
GingerF
avalanche
aaaa
老胡
潇洒的惋清
皖公网安备34019202002308
